LSBio
IHC-plus™ FGF2 / Basic FGF Antibody (clone 3D9)

Anti-FGF2 / Basic FGF antibody IHC staining of human brain, cortex. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/ml.

IHC-plus™ FGF2 / Basic FGF Antibody (clone 3D9)

Primary AntibodyLSBio Guarantee
Antibody:Mouse Monoclonal
Applications:Immunofluorescence, Immunohistochemistry (general), Immunohistochemistry, Paraffin, Western Blot
Reactivity:Human
Format:Liquid
See all FGF2 / Basic FGF antibodies →
$383.00each
Catalog Number: LS-B10042-50

For bulk orders or custom formulations:

Request a Quote

Overview

Description
Basic FGF antibody LS-B10042 is an unconjugated mouse monoclonal antibody to human Basic FGF (FGF2). Validated for IF, IHC and WB. Tested on 20 paraffin-embedded human tissues. Cited in 1 publication.
Application
IF, IHC, IHC-P, WB
Reactivity
Hu
Intended Use
Research Use Only
Guarantees
This product carries the LSBio 100% Guarantee.
Category
Antibodies > Primary Antibodies > Monoclonal Antibodies
Alternative Names
Basic fibroblast growth factor | FGFB | Fibroblast growth factor 2 | FGF-2 | Prostatropin | BFGF | FGF2 | HBGF-2
Recommended Dilution: IF/ICC
1:100
Recommended Dilution: IHC-P
10 µg/ml
Recommended Dilution: WB
1:1000
UniProt Number
P09038
SwissProt
P09038

Target

Target
FGF2 / Basic FGF
Antigen Species
Human
Specificity
Human FGF2 / BFGF
Epitope
Human FGF2 / BFGF
Gene Name
FGF2

Antibody

Host Species
Mouse
Clonality
Monoclonal
Clone
3D9
Origin Species
Human

Immunogen

Immunogen
Human recombinant protein fragment corresponding to amino acids 10-155 of human bFGF (NP_001997) produced in E. coli.
Immunogen Type
Recombinant Protein Fragment

Format

Conjugate/Label
Unconjugated
Format
Liquid
Formulation
PBS, pH 7.3, 0.02% Sodium Azide, 50% Glycerol, 1% BSA
Concentration
1 mg/mL
Volume
50 Microliter
Animal Free
No
Carrier-Free
No
Preservative
Yes
Purification Method
Protein A/G Affinity

Storage & Handling

Storage Conditions
Store at -20°C. Avoid freeze-thaw cycles.
Recommended Storage Buffer
PBS
A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma10 Washington University School of Medicine, St. Louis, MO, USA12 Memorial Sloan Kettering Cancer Center, New York, NY, USA14 GlaxoSmithKline, Inc., 1250 South Collegeville Road, Collegeville, PA, USA16 Utrecht University, Utrecht, The Netherlands18 Phase I Trials Unit, Medical Oncology Department, Hospital Universitario Virgen de. Emilie M J van Brummelen, Evgeny Levchenko, Manuel Dómine, Dean A Fennell, Hedy L Kindler, Santiago Viteri, Shirish Gadgeel, Pilar Garrido López, Vladimir Kostorov, Daniel Morgensztern, Sergey Orlov, Marjorie G Zauderer, Johan F Vansteenkiste, Katherine Baker-Neblett, James Vasquez, Xiaowei Wang, David I Bellovin, Jan H M Schellens, Li Yan, Ionel Mitrica, M Phillip DeYoung, José Trigo. Investigational new drugs. 2020 Apr;;38:457-467. PubMed: 31065954 PMC: PMC6898757

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at: technical@vectorlabs.com.